Enjamb Labs
<!-- hacklab:yc-profile -- YC company profile The AI Workforce for Biopharma We've worked with 130 life science companies, preclinical through phase 3, to deploy AI securely ins…
About Enjamb Labs
YC company profile
The AI Workforce for Biopharma
We've worked with 130 life science companies, preclinical through phase 3, to deploy AI securely inside the systems they already work in.
Pharma runs on decades of closed software like Benchling, Veeva, Medidata, and SAS. None of it has an AI layer or speaks MCP, so agents cannot reach the systems where the work lives.
Enjamb is that layer. Our agents run on top of existing systems and data, with no migration, and they reach the lab systems and internal tools no other AI touches. They learn how a team works, then do the work in Slack, in Teams, and in the systems themselves, across preclinical research, clinical evidence, trial design, statistical programming, and regulatory submissions.
This is AI tailored for how medicine gets made.
- YC batch: Spring 2026
- Founded: 2025
- Team size: 2
- Location: San Francisco
- Country: US
- Status: Active
- Industry: B2B
- Stage: Early
- Tags: SaaS, B2B, Biotech, Automation, AI
- YC partner: Nicolas Dessaigne
Founders
Rayan Mubarak — Founder/CEO
Co-founder of Enjamb. I'm an ML and biology researcher. At 17, I published a first-author cancer ML paper in JMIR that beat SOTA models by 20%. Previously, I researched drug therapeutics for pesticide poisoning (30% more effective) and presented at top bio conferences (SOT, ISCB).
Source: Y Combinator · Retrieved 2026-11-02. Company information is self-reported on YC.